Equities

Key statistics

As of last trade Novo Nordisk A/S (NOVO B:CPH) traded at 432.95, -5.12% below its 52-week high of 456.30, set on Jun 19, 2020.
52-week range
Today
312.00Jul 15 2019456.30Jun 19 2020
Markit short selling activity
Low
Med
High
Open437.00
High438.45
Low432.00
Bid432.90
Offer432.95
Previous close436.60
Average volume2.84m
Shares outstanding1.81bn
Free float1.13bn
P/E (TTM)25.59
Market cap791.37bn DKK
EPS (TTM)17.06
DKK
Annual div (ADY)8.35
DKK
Annual div yield (ADY)1.91%
Div ex-dateMar 27 2020
Div pay-dateMar 31 2020
Data delayed at least 15 minutes, as of Jul 06 2020 11:06 BST.
More ▼

Board of Directors

1/5

Sten Scheibye, Chairman of the Board

2/5

Göran A. Ando, Vice Chairman of the Board

3/5

Henrik Gürtler, Member of the Board

4/5

Ulrik Hjulmand-Lassen, Member of the Board (Employee Representative)

5/5

Pamela J Kirby, Member of the Board

Further Information

Investor Relations Contact

Klaus Bülow Davidsen
Head of Investor Relations
Corporate Vice President

Novo Allé
2880 Bagsværd
Denmark

Tel: +45 4442 3176
Mobile: +45 3079 3176
Fax: +45 4444 6626
e-mail: klda@novonordisk.com

The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.